Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Budget Proposal Shifts More Toward User Fees Reliance

This article was originally published in The Tan Sheet

Executive Summary

User fees make up the bulk of FDA’s human drug spending under President Obama’s fiscal 2014 budget proposal, a trend fueled by new user fee programs and cuts to taxpayer funding.


Related Content

New Food And Drug User Fees Face Long Odds In Congress
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
HELP Committee Leaders Add Voice To Doubts About New User Fees
Battle Lines Clear On Conflict Of Interest Policy In PDUFA Reauthorization





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts